In human IPF patients, two phase III trials have shown that treatment with pirfenidone, an agent inhibiting TGF-β activity and p38 mitogen-activated protein kinase (MAPK) signaling, improved pulmonary function[94,95]. Here, TGFB1 is linked to idiopathic pulmonary fibrosis.